Pharming Group (NASDAQ:PHAR) Shares Gap Up - Here's What Happened

Key Points

• Pharming Group's stock price gapped up from $13.86 to $14.68 before opening on Friday, with a last-traded price of $14.72 and a trading volume of 3,915 shares.
• The company reported a profit of $0.06 per share, surpassing analysts' expectations of a loss, and had revenues of $93.20 million for the quarter, significantly higher than the estimated $70.36 million.
• Institutional investors have shown interest, with EverSource Wealth Advisors acquiring a stake valued at approximately $32,000, indicating growing interest in Pharming Group by hedge funds and others.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $13.86, but opened at $14.68. Pharming Group shares last traded at $14.72, with a volume of 3,915 shares traded.

Pharming Group Trading Down 0.3%

The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.07 and a current ratio of 2.79. The business has a fifty day moving average of $12.50 and a 200-day moving average of $10.58. The company has a market capitalization of $1.02 billion, a P/E ratio of -114.08 and a beta of 0.05.

Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.16. Pharming Group had a negative return on equity of 3.31% and a negative net margin of 2.19%.The business had revenue of $93.20 million for the quarter, compared to analysts' expectations of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. Analysts anticipate that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC bought a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 2,979 shares of the company's stock, valued at approximately $32,000. Institutional investors own 0.03% of the company's stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.